RecallDepth
Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical, Inc., Berkley Heights, NJ 07922, NDC 51991-747-10.

This recall is currently active, issued April 9, 2025. It was issued by Breckenridge Pharmaceutical, Inc..

Company
Breckenridge Pharmaceutical, Inc.
Recall Initiated
March 26, 2025
Posted
April 9, 2025
Recall Number
D-0308-2025
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
14,863 bottles
Firm Location
Berkeley Heights, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.

Distribution

Nationwide in the US

Lot / Code Info

Lot 240909C, Exp Date 03/31/2027

More recalls by Breckenridge Pharmaceutical, Inc.

View all recalls by this company →

Other recent Class II Drug recalls